U.S. markets closed


NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
7.10-0.04 (-0.56%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close7.14
Bid6.74 x 800
Ask7.37 x 2900
Day's Range7.00 - 7.44
52 Week Range5.00 - 7.88
Avg. Volume57,746
Market Cap237.609M
Beta (5Y Monthly)N/A
PE Ratio (TTM)1,014.29
EPS (TTM)0.01
Earnings DateAug 23, 2022 - Aug 29, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.57
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for EDAP

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    Analyst Report: Medtronic plcOne of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
    Fair Value
    Economic Moat
    2 days agoMorningstar
View more
  • GlobeNewswire

    EDAP Reports First Quarter 2022 Results

    First quarter 2022 revenue of approximately EUR 13.0 million (USD 14.5 million), an increase of 26% as compared to EUR 10.3 million (USD 12.4 million) for the first quarter 2021Four Focal One units sold in Q1 2022 versus zero in Q1 2021Strong cash position of $51.6 million as of March 31, 2022Company to host a conference call tomorrow, Wednesday, May 18, at 8:30 am ET LYON, France, May 17, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (the “Company”), a global leader in robotic energy-based therapies, anno

  • GlobeNewswire

    EDAP TMS SA to Announce First Quarter 2022 Financial Results on May 17, 2022

    Company to host conference call and webcast on, Wednesday, May 18th at 8:30 am EDT LYON, France, May 10, 2022 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the first quarter ended March 31st, 2022 after the markets close on Tuesday, May 17th, 2022. An accompanying conference call and webcast will be hosted by Marc Oczachowski, Chairman of the Board and Chief Executive Officer, Ryan Rhodes, CEO of

  • GlobeNewswire

    EDAP to Showcase its Focal One® Platform at the Annual Meeting of the American Urological Association (AUA)

    AUA is the largest annual gathering of urologists worldwide LYON, France, May 5, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that the company will be showcasing and exhibiting its Focal One® Robotic High Intensity Focused Ultrasound (HIFU) platform at the upcoming Annual Meeting of the American Urological Association (AUA), the largest gathering of urologists worldwide, which will be held May 13th through 15th in New Or